Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejca.2019.07.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.
Lancet Glob Health
July 2021
Center for Global Health, National Cancer Institute, Rockville, MD, USA. Electronic address:
Background: There are no clinical trials involving patients with diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa since antiretroviral therapy (ART) for HIV became widely available in this region. We aimed to establish the safety and efficacy of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with DLBCL in Malawi.
Methods: This prospective, single-arm, non-randomised phase 1/2 clinical trial was done at Kamuzu Central Hospital Cancer Clinic (Lilongwe, Malawi).
Case 285: Primary Breast Lymphoma.
Radiology
January 2021
From the Departments of Radiology (M.E.K., I.T., L.L.), Pathology (A.M.), and Nuclear Medicine (A.T.), Centre Hospitalier Universitaire de Montréal (CHUM), 1051 Rue Sanguinet, Montréal, QC, Canada H2X 3H4; and Department of Radiology, McGill University Health Centre, Montréal, Quebec, Canada (B.M.).
History A 25-year-old woman was referred to our breast clinic for assessment of a palpable mass in her left breast that developed quickly in 2 weeks. She denied any associated fever, chills, redness, or pain. She had no relevant medical or surgical history; no evidence of recent pregnancy, abortion, or breastfeeding; and no family history of breast cancer.
View Article and Find Full Text PDFBreastfeeding during R-CHOP chemotherapy: please abstain!
Eur J Cancer
September 2019
European Institute of Oncology IRCCS, Division of Gynecologic Oncology, Milan, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!